Veterinary Formulations Comprising Rapamycin and Methods of Using the Same for Treating Animal Disease
Summary
The USPTO granted Patent US12599590B2 to TriviumVet DAC covering veterinary formulations comprising rapamycin or rapalogs for treating animal diseases including cardiac dysfunction, hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, cancer, effects of aging, inflammatory disease, and viral infection in companion animals. The patent contains 15 claims and was filed on December 18, 2020.
What changed
The USPTO granted Patent US12599590B2 to TriviumVet DAC, giving the company exclusive intellectual property rights to veterinary formulations containing rapamycin or rapalogs. The patent covers methods of treating cardiac dysfunction (including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, and pressure-overload cardiac hypertrophy), cancer, effects of aging, inflammatory disease, and viral infections in companion animals.
Competitors developing similar rapamycin-based veterinary formulations without licensing the patent may face infringement claims. The patent grant strengthens TriviumVet's IP position in the animal health pharmaceutical sector and may influence competitive R&D activities in this therapeutic area.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Veterinary formulations comprising rapamycin and methods of using the same for treating animal disease
Grant US12599590B2 Kind: B2 Apr 14, 2026
Assignee
TriviumVet DAC
Inventors
Tom Brennan, Louise Grubb, Liam Byrne, Stuart Fitzgerald
Abstract
The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.
CPC Classifications
A61K 31/436 A61K 9/2013 A61K 9/2018 A61K 9/2027 A61K 9/2031 A61K 9/2054 A61K 9/2077 A61K 9/2813 A61K 9/282 A61K 9/2846 A61K 31/675 A61P 9/00
Filing Date
2020-12-18
Application No.
17777800
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.